{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:11:33Z","timestamp":1774923093412,"version":"3.50.1"},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2005,8,16]],"date-time":"2005-08-16T00:00:00Z","timestamp":1124150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:p>Objective.\u2014To assess changes in health\u2010related quality of life (HRQoL) measures among patients receiving topiramate (TPM) 100 mg\/d in two divided doses for migraine prevention in three randomized, double\u2010blind, placebo\u2010controlled, 26\u2010week trials with similar protocols and study populations.<\/jats:p>\n                  <jats:p>Background.\u2014Migraine substantially impairs HRQoL and work productivity before, during, and after attacks. Approximately 50% of patients with migraine could be recommended for preventive therapies, yet only 3% to 5% of patients receive them. TPM is an effective and generally well\u2010tolerated migraine prophylactic (preventive) therapy for adults, as demonstrated in several randomized, double\u2010blind, placebo\u2010controlled trials. The most common adverse events in double\u2010blind, placebo\u2010controlled studies of TPM in migraine prevention are paresthesia, fatigue, anorexia, nausea, taste alteration, and diarrhea.<\/jats:p>\n                  <jats:p>Design and Methods.\u2014The Migraine\u2010Specific Questionnaire (MSQ, version 2.1) was used to assess the effect of TPM 100 mg\/d on the functionality and HRQoL of randomized intent\u2010to\u2010treat (ITT) and study\u2010completer populations pooled from three randomized, double\u2010blind, placebo\u2010controlled trials. MSQ scores (0 to 100, higher score indicates better functioning) were assessed for the following three domains: role restriction (examines the degree to which performance of daily activities is limited by migraine), role prevention (examines the degree to which performance of daily activities is interrupted by migraine), and emotional function (examines feelings of frustration and helplessness due to migraine). Between\u2010group differences from baseline in mean MSQ domain scores for TPM 100 mg\/d and placebo were compared using a mixed\u2010effects model with piecewise linear regression. Effect sizes were calculated to estimate the magnitude of change in HRQoL that can be associated with TPM therapy.<\/jats:p>\n                  <jats:p>\n                    Results.\u2014TPM 100 mg\/d significantly improved all three MSQ domains compared with placebo for both the ITT (TPM, n = 372; placebo, n = 362) and study\u2010completer (TPM, n = 220; placebo, n = 216) populations (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .001 for all three domains, both populations). Effect sizes for TPM 100 mg\/d varied from 0.40 to 0.78, indicating that the changes in MSQ scores for TPM 100 mg\/d were moderate and may be clinically significant.\n                  <\/jats:p>\n                  <jats:p>Conclusion.\u2014TPM 100 mg\/d has been shown to be effective in the prevention of migraine headache in adults. As the MSQ results from the three randomized, placebo\u2010controlled trials indicate, HRQoL is significantly improved for up to 6 months following initiation of treatment.<\/jats:p>","DOI":"10.1111\/j.1526-4610.2005.05183.x","type":"journal-article","created":{"date-parts":[[2005,8,16]],"date-time":"2005-08-16T09:54:22Z","timestamp":1124186062000},"page":"1023-1030","source":"Crossref","is-referenced-by-count":49,"title":["Topiramate Improves Health\u2010Related Quality of Life When Used to Prevent Migraine"],"prefix":"10.1111","volume":"45","author":[{"given":"Merle","family":"Diamond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Dahl\u00f6f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"S\u2010C","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,8,16]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007638.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1993.hed3301029.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1995.hed3504200.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100047697"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480010072027"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1701015.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1996.3603137.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1997.3702071.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.5.624"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3806423.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.qjmed.a030141"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007710.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6424.1126"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1995.1501031.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.8.813"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.3_Suppl_3.4S"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3802087.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.8.965"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.490"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-0464-6"},{"key":"e_1_2_7_22_2","unstructured":"FarkkilaM BussoneG D'AmicoD JacobsD NetoW PfeilJ.The efficacy of topiramate in migraine prevention: analyses of pooled data from three 26\u2010week placebo\u2010controlled double\u2010blind topiramate trials.Poster presented at the 2004 Migraine Trust International Symposium September 20\u201023. London UK 2004."},{"key":"e_1_2_7_23_2","unstructured":"AdelmanJ LainezMJA JacobsD NetoW ShiY.Analysis of safety data obtained from over 1500 patients receiving topiramate for migraine prevention.Poster presented at the 2004 Annual Meeting of the American Headache Society June 10\u201013. Vancouver Canada 2004."},{"key":"e_1_2_7_24_2","volume-title":"Topiramate Prescribing Information","year":"2004"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00030.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3804295.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199813060-00007"},{"key":"e_1_2_7_28_2","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen J","year":"1988"},{"key":"e_1_2_7_29_2","volume-title":"Meta\u2010analysis in Social Research","author":"Glass GV","year":"1981"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0269-4727.2003.00521.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7167.1191"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S29"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7297.1297"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.111006343.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03040.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000052687.03646.74"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550160012009"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03023.x"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.4.427"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1526-4610.2005.05183.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1526-4610.2005.05183.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:54:28Z","timestamp":1762091668000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/j.1526-4610.2005.05183.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,16]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1111\/j.1526-4610.2005.05183.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1526-4610.2005.05183.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,16]]}}}